Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Frontline Atezolizumab Plus Chemotherapy Elicits PFS Benefit in Advanced/Recurrent Endometrial Cancer

October 21st 2023

Atezolizumab plus standard-of-care platinum-based chemotherapy, followed by maintenance therapy with atezolizumab monotherapy, improved progression-free survival vs chemotherapy plus placebo, followed by placebo maintenance therapy, in the frontline treatment of patients with advanced or recurrent endometrial carcinoma particularly in those with mismatch repair–deficient disease.

Pembrolizumab Plus Chemoradiotherapy Shows Statistically Significant PFS Benefit vs SOC in High-Risk Locally Advanced Cervical Cancer

October 20th 2023

The addition of pembrolizumab to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, resulted in statistically significant and clinically meaningful improvements in progression-free survival when compared with placebo plus EBRT/chemoradiotherapy/brachytherapy in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

CHMP Recommends Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced/Recurrent Endometrial Cancer

October 16th 2023

The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of dostarlimab plus chemotherapy for the treatment of adult patients with mismatch repair–deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer.

Dostarlimab Plus Chemo Wins MHRA Approval for dMMR/MSI-H Primary Advanced/Recurrent Endometrial Cancer

October 6th 2023

The Medicines and Healthcare Products Regulatory Agency has authorized the use of dostarlimab in combination with chemotherapy for the treatment of patients with mismatch repair-deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer.

The Future of Clinical Care for Patients With Advanced Endometrial Cancer

October 6th 2023

Closing their conversation, Ramez Eskander, MD, and Krishnansu Tewari, MD, share how they envision the future treatment landscape for patients with advanced endometrial cancer.

Emerging Targeted Treatment Options for Patients With Advanced Endometrial Cancer

October 6th 2023

Key opinion leaders discuss targeted treatment regimens for advanced or recurrent endometrial cancer that are currently under development.

Patient Profile Presentation: A 68-Year-Old Woman With Recurrent Endometrial Cancer

September 29th 2023

Krishnansu Tewari, MD, presents the profile of a 68-year-old postmenopausal woman with recurrent endometrial cancer for discussion.

Approaches to Treatment Sequencing for Patients With Advanced Endometrial Cancer

September 29th 2023

Experts explain how they change their treatment strategies if a patient with advanced endometrial cancer does not respond to treatment or experiences disease progression.

Recent Data on IO-Based Combination Regimens for First-line Treatment of Advanced Endometrial Carcinoma

September 22nd 2023

Krishnansu Tewari, MD, reviews emerging data from two studies investigating immunotherapy-based combination regimens for the first-line treatment of advanced endometrial cancer.

Available Frontline Treatment Options for Patients With Advanced or Recurrent Endometrial Cancer

September 22nd 2023

Krishnansu Tewari, MD, details the first-line treatment options for patients with recurrent endometrial cancer.

FDA Grants Priority Review to Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer

September 20th 2023

The FDA has granted priority review to a supplemental biologics license application seeking the approval of pembrolizumab in combination with external beam radiotherapy plus concurrent chemotherapy, followed by brachytherapy, for the treatment of newly diagnosed patients with high-risk, locally advanced cervical cancer.

Patient Profile Presentation: A 64-Year-Old Woman With Recurrent Endometrial Cancer

September 15th 2023

Ramez Eskander, MD, presents the profile of a 64-year-old postmenopausal woman diagnosed with recurrent endometrial carcinoma for discussion.

Overview of Endometrial Carcinoma

September 15th 2023

Ramez Eskander, MD, and Krishnansu Tewari, MD, provide an overview of endometrial cancer, including prevalence, staging criteria, and molecular profiling.

FDA Grants Fast Track Status to Tulmimetostat for Endometrial Cancer

September 13th 2023

The FDA has granted fast track designation to tulmimetostat for use as a potential therapeutic option in patients with advanced, recurrent, or metastatic endometrial cancer harboring ARID1A mutations and whose disease had progressed on at least 1 prior line of therapy.

Dr Birrer on Molecular Stratification in Endometrial Cancer

September 8th 2023

Michael J. Birrer, MD, PhD, discusses the benefits of molecular profiling in patients with endometrial cancer, the variety of mutations that have been identified in this disease, and how stratifying patients based on the biomarkers their disease harbors allows for more individualized treatment decisions.

Dr Pothuri on the Promise of the RUBY and NRG-GY018 Trials in Endometrial Cancer

September 7th 2023

Bhavana Pothuri, MD, discusses the promise of the phase 3 NRG-GY018 and RUBY trials in patients with endometrial cancer.

Tisotumab Vedotin Improves OS in Recurrent/Metastatic Cervical Cancer

September 5th 2023

Treatment with tisotumab vedotin-tftv monotherapy led to an improvement in overall survival compared with chemotherapy alone in patients with recurrent or metastatic cervical cancer that progressed on or after frontline therapy.

Prolgolimab Combo Shows Antitumor Activity and Safety in Advanced Cervical Cancer

September 1st 2023

Administration of the anti–PD-1 antibody prolgolimab in combination with bevacizumab and platinum-doublet chemotherapy resulted in high response rates and a favorable safety profile in patients with recurrent or metastatic cervical cancer.

Dr Santin on the Investigation of Sacituzumab Govitecan in Endometrial Cancer

August 30th 2023

Alessandro Santin, MD, discusses the investigation of sacituzumab govitecan in patients with recurrent endometrial carcinoma overexpressing TROP2.

Geptanolimab Elicits Durable Responses and Acceptable Safety in PD-L1+ Cervical Cancer

August 29th 2023

The novel anti-PD-1 antibody geptanolimab demonstrated durable antitumor activity and favorable tolerability in patients with recurrent or metastatic PD-L1–positive cervical cancer who previously progressed on a platinum-based regimen.